Star Witness In Martoma Trial Lied To FBI

Jan 22 2014 | 12:49pm ET

The prosecution's star witness against former SAC Capital Advisors trader Mathew Martoma admitted he lied to investigators for more than a year before agreeing to cooperate with the government in the insider-trading case.

Sidney Gilman's testimony was cut short by yesterday's snowstorm in New York—he'll be back on the stand today to face cross-examination—but under questioning by prosecutors, he said he lied to the Federal Bureau of Investigation when first approached in September 2011.

"I was so intensely ashamed," Gilman, a former University of Michigan medical professor, told the jury. "I was hoping the whole thing would go away."

The "whole thing," Gilman said, was the confidential information about an Alzheimer's drug trial that he passed to Martoma, allowing Martoma to allegedly earn or save SAC $276 million. Gilman said he warned Martoma that the trial was not going well in July 2008, nearly two weeks before he was set to present the findings to other Alzheimer's specialists and just a day after he learned himself.

Gilman led the trial's safety committee. He has been given immunity from prosecution.

The following summer, Gilman said he came clean, telling "the government that I had provided inside information to Mr. Martoma repeatedly."

Gilman, like Joel Ross, another doctor who admitted he passed information about the trials to Martoma, said the hedge-fund manager was particularly interested in one side-effect, a type of brain swelling that could have been a sign that the drug was working.

The 81-year-old told the jury that he kept Martoma up to date in "minute detail," frequently speaking to him within a couple of days of the safety committee's meetings. "He frequently asked me to pause or to go more slowly was I was telling him numbers," Gilman said.

Gilman also gave confidential information to a former SAC healthcare analyst, David Munno, at Martoma's request. Munno has not been charged with wrongdoing and could be called as a witness.


In Depth

Q&A: Neil Azous Talks Global Macro Investing

Nov 24 2014 | 12:41pm ET

Neil Azous is the founder and managing member of Rareview Macro, an advisory firm...

Lifestyle

Griffin Selling Chicago Apartment

Nov 26 2014 | 11:40am ET

Citadel Investment Group’s Kenneth Griffin is making clear to his estranged wife...

Guest Contributor

Why The Big Money Is Going To Europe

Nov 14 2014 | 6:03am ET

Peer-to-peer lending was invented with the individual investor in mind. But despite...

 

Sponsored Content

    For Hedge Funds, Mastering Data Is Key To Success

    Nov 4 2014 | 9:45am ET

    Data management is important to every business, but for hedge funds, it is critical. FINalternatives recently asked Peter Sanchez, CEO of Northern Trust Hedge Fund Services, how fund managers can deal with the demands of managing data while at the same time remain transparent and abide by operational best practices. Read more…

Editor's Note

    Guidelines for Guest Articles

    Oct 22 2014 | 9:46am ET

    We are always looking for guest articles from hedge fund managers and buy-side firms.

    If you are interested in submitting a contributed piece for possible publication on FINalternatives, please take a look at the specs. Read more…

 

Futures Magazine

November 2014 Cover

Building a better market

Reg NMS created a huge bifurcation in equity markets and while much of what has followed has been positive, in terms of lower fees and greater liquidity, many traders would like to see the market come...

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.